Endometrial Adenocarcinoma
54
7
13
31
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Published Results
20 trials with published results (37%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
3.7%
2 terminated out of 54 trials
93.9%
+7.4% vs benchmark
6%
3 trials in Phase 3/4
65%
20 of 31 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 31 completed trials
Clinical Trials (54)
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
DBC-664 in Adult Patients With Solid Tumors
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
Comparison of Sentinel Lymph Node Applications in Endometrial Cancer Cases Performed With Vaginal Natural Orifice Transluminal Endoscopic Surgery (V-NOTES) and Conventional Laparoscopy
Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care
Prognosis of METTL-14 in Endometrial Carcinoma
Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Treatment
V-Notes Hysterectomy in Patients With Endometrial cáncer Compared With Laparoscopic Surgery (Robotically Assisted or Not): ENOLA TRIAL
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
PErsonalized TReatment for Endometrial Carcinoma
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
[SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer